Calcineurin inhibitor sparing with mycophenolate in kidney transplantation: A systematic review and meta-analysis

Transplantation

Volumn 87, Issue 4, 2009, Pages 591-605

  Moore, Jason ^a   Middleton, Lee ^b   Cockwell, Paul ^a   Adu, Dwomoa ^a   Ball, Simon ^a   Little, Mark A ^a   Ready, Andrew ^a   Wheatley, Keith ^b   Borrows, Richard ^a  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Cyclosporine; Kidney transplantation; Meta analysis; Mycophenolate; Tacrolimus

Indexed keywords

CREATININE; CYCLOSPORIN A; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; CALCINEURIN; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT REJECTION; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG WITHDRAWAL; FOLLOW UP; GLOMERULUS FILTRATION RATE; GRAFT FAILURE; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; META ANALYSIS; MORTALITY; PATIENT SELECTION; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTEMATIC REVIEW; DRUG ANTAGONISM; DRUG COMBINATION; GRAFT REJECTION; IMMUNOLOGY; REVIEW; STANDARD; STATISTICS; SURVIVAL; TREATMENT OUTCOME;

CALCINEURIN; DRUG THERAPY, COMBINATION; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MYCOPHENOLIC ACID; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 65649141573     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e318195a421     Document Type: Article

References (50)

1. Cyclosporin in cadaveric renal transplantation: One-year follow-up of a multicentre trial. Lancet 1983; 2: 986.
2. A randomized clinical trial of cyclosporine in cadaveric renal transplantation. Analysis at three years. The Canadian Multicentre Transplant Study Group. N Engl J Med 1986; 314: 1219.
3. Webster AC, Woodroffe RC, Taylor RS, et al. Tacrolimus versus ciclosporinas primary immunosuppression for kidney transplant recipients: Meta-analysis and meta-regressionof randomised trial data. BMJ 2005; 331: 810.
4. Meier-Kriesche HU, Schold JD, Srinivas TR, et al. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004; 4: 378.
5. Nankivell BJ, Borrows RJ, Fung CL,et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 2326.
6. Ligtenberg G, Hene RJ, Blankestijn PJ, et al. Cardiovascular risk factors in renal transplant patients: Cyclosporin A versus tacrolimus. J Am Soc Nephrol 2001; 12: 368.
7. Kasiske BL, Chakkera HA, Louis TA, et al. A meta-analysis of immunosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol 2000; 11: 1910.
8. Mulay AV, Hussain N, Fergusson D, et al. Calcineurin inhibitor withdrawal from sirolimus-based therapy in kidney transplantation: A systematic review of randomized trials. Am J Transplant 2005; 5: 1748.
9. Mulay AV, Cockfield S, Stryker R, et al. Conversion from calcineurin inhibitors to sirolimus for chronic renal allograft dysfunction: A systematic review of the evidence. Transplantation 2006; 82: 1153.
10. Asberg A, Midtvedt K, Line PD, et al. Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR-matched de novo kidney transplant recipients. Transplantation 2006; 82: 62.
11. Jadad AR, Moore RA, CarrollD,et al. Assessing the qualityof reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 1996; 17: 1.
12. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 719.
13. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977; 35: 1.
14. Early Breast Cancer Trialists' Collaborative Group. Treatment of Early Breast Cancer. Worldwide Evidence 1985-1990. Oxford, Oxford University Press 1990.
15. Fleiss JL. The statistical basis of meta-analysis. Stat Methods Med Res 1993; 2: 121.
16. Moher D, Cook DJ, Eastwood S, et al. Improving the quality of reports of meta-analyses of randomised controlled trials: The QUOROM statement. Quality of Reporting of Meta-analyses. Lancet 1999; 354: 1896.
17. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562.
18. Hernandez D, Miquel R, Porrini E, et al. Randomized controlled study comparing reduced calcineurin inhibitors exposure versus standard cyclosporine-based immunosuppression. Transplantation 2007; 84: 706.
19. Budde K, Bosmans JL, Sennesael J, et al. Reduced-exposure cyclosporine is safe and efficacious in de novo renal transplant recipients treated with enteric-coated mycophenolic acid and basiliximab. Clin Nephrol 2007; 67: 164.
20. de Sevaux RG, Gregoor PJ, Hene RJ, et al. A controlled trial comparing two doses of cyclosporine in conjunction with mycophenolate mofetil and corticosteroids. J Am Soc Nephrol 2001; 12: 1750.
21. Cibrik D, Meier-Kriesche HU, Bresnahan B, et al. Renal function with cyclosporine C2 monitoring, enteric-coated mycophenolate sodium and basiliximab: A 12-month randomized trial in renal transplant recipients. Clin Transplant 2007; 21: 192.
22. Vincenti F, Mendez R, Curtis J, et al. A multicenter, prospective study of C2-monitored cyclosporine microemulsion in a U.S. population of de novo renal transplant recipients. Transplantation 2005; 80: 910.
23. Stefoni S, Midtved K, Cole E, et al. Efficacy and safety outcomes among de novo renal transplant recipients managed by C2 monitoring of cyclosporine a microemulsion: Results of a 12-month, randomized, multicenter study. Transplantation 2005; 79: 577.
24. Pascual M, Curtis J, Delmonico FL, et al. A prospective, randomized clinical trial of cyclosporine reduction in stable patients greater than 12 months after renal transplantation. Transplantation 2003; 75: 1501.
25. Ekberg H, Grinyo J, Nashan B, et al. Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: The CAESAR Study. Am J Transplant 2007; 7: 560.
26. Hazzan M, Labalette M, Copin MC, et al. Predictive factors of acute rejection after early cyclosporine withdrawal in renal transplant recipients who receive mycophenolate mofetil: Results from a prospective, randomized trial. J Am Soc Nephrol 2005; 16: 2509.
27. Baczkowska T, Perkowska-Francka A, Durlik M, et al. The role of the protocol biopsies in renal allograft recipients. Transplant Proc 2003; 35: 2179.
28. Abramowicz D, Manas D, Lao M, et al. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen in stable kidney transplant recipients: A randomized, controlled study. Transplantation 2002; 74: 1725.
29. Smak Gregoor PJ, de Sevaux RG, Ligtenberg G, et al. Withdrawal of cyclosporine or prednisone six months after kidney transplantation in patients on triple drug therapy: A randomized, prospective, multi-center study. J Am SocNephrol 2002; 13: 1365.
30. Schnuelle P, van der Heide JH, Tegzess A, et al. Open randomized trial comparing early withdrawal of either cyclosporine or mycophenolate mofetil in stable renal transplant recipients initially treated with a triple drug regimen. J Am Soc Nephrol 2002; 13: 536.
31. Frimat L, Cassuto-Viguier E, Charpentier B, et al. Impact of cyclosporine reduction with MMF: A randomized trial in chronic allograft dysfunction. The 'reference' study. Am J Transplant 2006; 6: 2725.
32. Stoves J, Newstead CG, Baczkowski AJ, et al. A randomized controlled trial of immunosuppression conversion for the treatment of chronic allograft nephropathy. Nephrol Dial Transplant 2004; 19: 2113.
33. Dudley C, Pohanka E, Riad H, et al. Mycophenolate mofetil substitution for cyclosporine a in renal transplant recipients with chronic progressive allograft dysfunction: The "creeping creatinine" study. Transplantation 2005; 79: 466.
34. Suwelack B, Gerhardt U, Hohage H. Withdrawal of cyclosporine or tacrolimus after addition of mycophenolate mofetil in patients with chronic allograft nephropathy. Am J Transplant 2004; 4: 655.
35. McGrath JS, Shehata M. Chronic allograft nephropathy: Prospective randomised trial of cyclosporin withdrawal and mycophenolate mofetil or tacrolimus substitution. Transplant Proc 2001; 33: 2193.
36. Abramowicz D, Del Carmen Rial M, Vitko S, et al. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: Results of a five-year, prospective, randomized study. J Am Soc Nephrol 2005; 16: 2234.
37. HazzanM, BuobD, Labalette M, et al. Assessment of the risk of chronic allograft dysfunction after renal transplantationin a randomized cyclosporine withdrawal trial. Transplantation 2006; 82: 657.
38. Webster AC, Lee VW, Chapman JR, et al. Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppres-sion in kidney transplant recipients. Cochrane Database Syst Rev 2006: CD004290.
39. Gourishankar S, Hunsicker LG, Jhangri GS, et al. The stability of the glomerular filtration rate after renal transplantationis improving. J Am Soc Nephrol 2003; 14: 2387.
40. Gill JS, Tonelli M, Mix CH, et al. The change in allograft function among long-term kidney transplant recipients. J Am Soc Nephrol 2003; 14: 1636.
41. HariharanS, Kasiske B, Matas A, et al. Surrogate markers for long-term renal allograft survival. Am J Transplant 2004; 4: 1179.
42. Anjum S, Andany MA, McClean JC, et al. Defining the risk of elective cyclosporine withdrawal in stable kidney transplant recipients. Am J Transplant 2002; 2: 179.
43. Munster J, van Son W, Baauw M. Withdrawal of cyclosporine after renal transplantation: A brisk pace may be detrimental. Transpl Int 2007: 20.
44. Naesens M, de Loor H, Vanrenterghem Y, et al. The impact of renal allograft function on exposure and elimination of mycophenolic acid (MPA) and its metabolite MPA 7-O-glucuronide. Transplantation 2007; 84: 362.
45. Cattaneo D, Merlini S, Zenoni S, et al. Influence of co-medication with sirolimus or cyclosporine on mycophenolic acid pharmacokinetics in kidney transplantation. Am J Transplant 2005; 5: 2937.
46. Dudley C, Pohanka E, Dedochova J. MMF substitution for CyA in chronic allograft dysfunction: 5 year follow up of a multi-centre randomized controlled trial. Transpl Int 2007; 20: 1.
47. Gallagher MP, Hall B, Craig J, et al. A randomized controlled trial of cyclosporine withdrawal in renal-transplant recipients: 15-year results. Transplantation 2004; 78: 1653.
48. Joss N, Rodger RS, McMillan MA, et al. Randomized study comparing cyclosporine with azathioprine one year after renal transplantation-15-year outcome data. Transplantation 2007; 83: 582.
49. Ciancio G, Burke GW III. Alemtuzumab (Campath-1H) in kidney transplantation. Am J Transplant 2008; 8: 15.
50. Vincenti F, Larsen C, Durrbach A, et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005; 353: 770.